(2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 2039-2054. http://doi.org/10.2147/copd.s408688.
Muscarinic Antagonists/adverse effects
(2022). Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting. Int J Chron Obstruct Pulmon Dis, 17, 2417-2429. http://doi.org/10.2147/copd.s370540.
(2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715-1733. http://doi.org/10.2147/copd.s363997.
(2021). Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. Int J Chron Obstruct Pulmon Dis, 16, 2591-2604. http://doi.org/10.2147/copd.s318969.